Patient clinical characteristics
| . | Median . | Range or % . |
|---|---|---|
| Age, y | 59 | 42-81 |
| Sex | 10 males/8 females | NA |
| BM, % | 12.5 | 2.5-80 |
| sIgM, mg/dL | 2625 | 610-5620 |
| Hb, g/dL | 11.0 | 8.1-14.4 |
| Adenopathy | 9 (50%) | NA |
| Splenomegaly | 7 (38.8%) | NA |
| Prior therapies | 1 | 0-4 |
| Untreated, n | 8 | 44.4% |
| Previously treated, n | 10 | 55.5% |
| Rituximab monotherapy | 2 | 20.0% |
| Alkylators | 7 | 70.0% |
| Nucleoside analogs | 5 | 50.0% |
| Proteasome inhibitors | 5 | 50.0% |
| . | Median . | Range or % . |
|---|---|---|
| Age, y | 59 | 42-81 |
| Sex | 10 males/8 females | NA |
| BM, % | 12.5 | 2.5-80 |
| sIgM, mg/dL | 2625 | 610-5620 |
| Hb, g/dL | 11.0 | 8.1-14.4 |
| Adenopathy | 9 (50%) | NA |
| Splenomegaly | 7 (38.8%) | NA |
| Prior therapies | 1 | 0-4 |
| Untreated, n | 8 | 44.4% |
| Previously treated, n | 10 | 55.5% |
| Rituximab monotherapy | 2 | 20.0% |
| Alkylators | 7 | 70.0% |
| Nucleoside analogs | 5 | 50.0% |
| Proteasome inhibitors | 5 | 50.0% |
Hb, hemoglobin; NA, not available; sIgM, serum IgM.